AU2002228608A1 - Amidated glucagon-like peptide-1 - Google Patents

Amidated glucagon-like peptide-1

Info

Publication number: AU2002228608A1
Authority: AU; Australia
Prior art keywords: amidated; glucagon; peptide; amidated glucagon
Prior art date: 2000-12-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002228608A

Inventor

Richard Dennis Dimarchi

Wolfgang Glaesner

Rohn Lee Junior Millican

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-13

Filing date

2001-11-30

Publication date

2002-06-24

2001-11-30 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

2002-06-24 Publication of AU2002228608A1 publication Critical patent/AU2002228608A1/en

Status Abandoned legal-status Critical Current

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
101800000224 Glucagon-like peptide 1 Proteins 0.000 title 1
102100040918 Pro-glucagon Human genes 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Toxicology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Crystallography & Structural Chemistry (AREA)
Materials Engineering (AREA)
Metallurgy (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AU2002228608A 2000-12-13 2001-11-30 Amidated glucagon-like peptide-1 Abandoned AU2002228608A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25525100P	2000-12-13	2000-12-13
US60/255,251		2000-12-13
PCT/US2001/043167 WO2002048192A2 (en)	2000-12-13	2001-11-30	Amidated glucagon-like peptide-1

Publications (1)

Publication Number	Publication Date
AU2002228608A1 true AU2002228608A1 (en)	2002-06-24

Family

ID=22967502

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AU2002228608A Abandoned AU2002228608A1 (en)	2000-12-13	2001-11-30	Amidated glucagon-like peptide-1
AU2002239262A Abandoned AU2002239262A1 (en)	2000-12-13	2001-12-06	Compositions of peptide crystals
AU2002233929A Abandoned AU2002233929A1 (en)	2000-12-13	2001-12-06	Compositions of peptide crystals

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
AU2002239262A Abandoned AU2002239262A1 (en)	2000-12-13	2001-12-06	Compositions of peptide crystals
AU2002233929A Abandoned AU2002233929A1 (en)	2000-12-13	2001-12-06	Compositions of peptide crystals

Country Status (4)

Country	Link
US (1)	US7199217B2 (en)
EP (1)	EP1351984A2 (en)
AU (3)	AU2002228608A1 (en)
WO (3)	WO2002048192A2 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (en)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2529300T3 (en)	2000-04-12	2015-02-18	Novozymes Biopharma Dk A/S	Albumin fusion proteins
CN1501809B (en)	2000-12-13	2012-10-10	伊莱利利公司	Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002316811A1 (en)	2001-06-28	2003-03-03	Novo Nordisk A/S	Stable formulation of modified glp-1
ES2425738T3 (en)	2001-12-21	2013-10-17	Human Genome Sciences, Inc.	Albumin Fusion Proteins
US7138105B2 (en) *	2002-02-27	2006-11-21	Pharmain	Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en) *	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
US7790681B2 (en)	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
US8008255B2 (en)	2003-05-30	2011-08-30	Amylin Pharmaceuticals, Inc.	Methods and compositions for enhanced transmucosal delivery of peptides and proteins
WO2004105790A1 (en)	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
WO2004105781A2 (en) *	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
CN102940879B (en) *	2003-06-03	2017-06-06	诺沃挪第克公司	Stabilized pharmaceutical peptide compositions
WO2005021022A2 (en) *	2003-09-01	2005-03-10	Novo Nordisk A/S	Stable formulations of peptides
HUE043210T2 (en)	2003-11-20	2019-08-28	Novo Nordisk As	Peptide formulations containing propylene glycol which are optimal for the preparation of injection devices
WO2005112977A2 (en) *	2004-04-23	2005-12-01	Pharmain, Ltd.	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
EP1789434B1 (en)	2004-08-31	2013-11-20	Novo Nordisk A/S	Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
CN102772787A (en)	2004-11-12	2012-11-14	诺和诺德公司	Stable formulations of insulinoptropic peptides
WO2006069779A1 (en) *	2004-12-30	2006-07-06	F. Hoffmann-La Roche Ag	Preparing of peptides with excellent solubility
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
MX2008001468A (en) *	2005-06-30	2008-04-07	Sod Conseils Rech Applic	Glp-1 pharmaceutical compositions.
CN101534846B (en)	2005-11-07	2014-11-05	印第安纳大学研究及科技有限公司	Glucagon analogs exhibiting physiological solubility and stability
CN100374462C (en) *	2005-11-21	2008-03-12	大连帝恩生物工程有限公司	Truncated glucagon-like peptide 1 (sGLP-1), preparation method and application
AU2006330610B2 (en)	2005-12-19	2012-08-16	Pharmain Corporation	Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
EP2007804B1 (en)	2006-04-20	2014-06-18	Amgen, Inc	Glp-1 compounds
CA2651855C (en)	2006-05-30	2011-08-02	Intarcia Therapeutics, Inc.	Two-piece, internal-channel osmotic delivery system flow modulator
WO2008021133A2 (en)	2006-08-09	2008-02-21	Intarcia Therapeutics, Inc.	Osmotic delivery systems and piston assemblies
US20120214965A1 (en) *	2011-02-23	2012-08-23	Elona Biotechnologies	Glargine proinsulin and methods of producing glargine insulin analogs therefrom
US10100098B2 (en)	2006-12-13	2018-10-16	Stelis Biopharma Private Limited	Insulin production methods and proinsulin constructs
CN101578102B (en)	2007-01-05	2013-07-17	印第安纳大学研究及科技有限公司	Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
AU2008216265B2 (en)	2007-02-15	2014-04-03	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
ES2402172T3 (en) *	2007-04-23	2013-04-29	Intarcia Therapeutics, Inc	Suspension formulation of insulinotropic peptides and uses thereof
US7960336B2 (en)	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en) *	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
AU2008318876B2 (en)	2007-10-30	2014-05-15	Indiana University Research And Technology Corporation	Compounds exhibiting glucagon antagonist and GLP-1 agonist activity
AU2008318986B2 (en)	2007-10-30	2014-12-04	Indiana University Research And Technology Corporation	Glucagon antagonists
US20090176892A1 (en)	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
DK2240155T3 (en)	2008-02-13	2012-09-17	Intarcia Therapeutics Inc	Devices, formulations and methods for the delivery of several beneficial agents
PA8830501A1 (en)	2008-06-17	2010-07-27	Univ Indiana Res & Tech Corp	GLUCAGON / GLP-1 RECEIVER CO-AGONISTS
CL2009001425A1 (en)	2008-06-17	2010-04-30	Univ Indiana Res & Tech Corp	Glucagon analogs with a large aromatic amino acid lacking an imidazole side chain that confers agonist activity at the gip receptor; pharmaceutical compositions; kit containing them and use to reduce weight gain, treat diabetes, or induce intestinal tract paralysis.
CN102088989B (en)	2008-06-17	2014-11-26	印第安纳大学研究及科技有限公司	Glucagon analogs with enhanced solubility and stability in physiological pH buffers
EP2376097A4 (en)	2008-12-19	2012-10-03	Univ Indiana Res & Tech Corp	AMID-BASED PEPTIDE PRODRUGS OF THE GLUCAGON SUPERFAMILY
MX2011013625A (en)	2009-06-16	2012-01-20	Univ Indiana Res & Tech Corp	Gip receptor-active glucagon compounds.
LT2462246T (en)	2009-09-28	2017-11-27	Intarcia Therapeutics, Inc	IMMEDIATE IMPLEMENTATION AND / OR TERMINATION OF IMMEDIATE STATIONARY SUPPLY
US20110097386A1 (en) *	2009-10-22	2011-04-28	Biodel, Inc.	Stabilized glucagon solutions
ES2583259T3 (en) *	2009-12-01	2016-09-20	Novo Nordisk A/S	New alpha-amidant peptidyl alpha-hydroxyglycine liases
WO2011075393A2 (en)	2009-12-18	2011-06-23	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
US8551946B2 (en)	2010-01-27	2013-10-08	Indiana University Research And Technology Corporation	Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
US20110223244A1 (en) *	2010-03-09	2011-09-15	Elan Pharma International Limited	Alcohol resistant enteric pharmaceutical compositions
RU2604067C2 (en)	2010-05-13	2016-12-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
CN103179976A (en)	2010-05-13	2013-06-26	印第安纳大学研究及科技有限公司	Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
US8778872B2 (en)	2010-06-24	2014-07-15	Indiana University Research And Technology Corporation	Amide based glucagon superfamily peptide prodrugs
MX377589B (en)	2010-12-16	2025-03-10	Novo Nordisk As	Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP2654773B1 (en)	2010-12-22	2018-10-03	Indiana University Research and Technology Corporation	Glucagon analogs exhibiting gip receptor activity
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN106117343B (en)	2011-04-12	2020-11-03	诺沃—诺迪斯克有限公司	Diacylated GLP-1 Derivatives
CA2839867A1 (en)	2011-06-22	2012-12-27	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
JP6179864B2 (en)	2011-06-22	2017-08-16	インディアナユニヴァーシティリサーチアンドテクノロジーコーポレイション	Glucagon / GLP-1 receptor co-agonist
JP6324315B2 (en)	2011-11-17	2018-05-16	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	Glucagon superfamily of peptides exhibiting glucocorticoid receptor activity
DK2827845T3 (en)	2012-03-22	2019-04-01	Novo Nordisk As	COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CA2868188A1 (en)	2012-03-22	2013-09-26	Novo Nordisk A/S	Compositions of glp-1 peptides and preparation thereof
US9745359B2 (en)	2012-05-18	2017-08-29	Adda Biotech Inc.	Protein and protein conjugate for diabetes treatment, and applications thereof
CN104487056A (en)	2012-06-20	2015-04-01	诺和诺德A/S（股份有限公司）	Tablet formulation comprising a peptide and a delivery agent
EP2864351B1 (en)	2012-06-21	2016-08-10	Indiana University Research and Technology Corporation	Glucagon analogs exhibiting gip receptor activity
AU2014261336B2 (en)	2013-05-02	2019-02-28	Novo Nordisk A/S	Oral dosing of GLP-1 compounds
CA2932477C (en)	2013-12-06	2023-10-10	Baikang (Suzhou) Co., Ltd	Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2987766A1 (en)	2015-06-03	2016-12-08	Intarcia Therapeutics, Inc.	Implant placement and removal systems
US10501517B2 (en)	2016-05-16	2019-12-10	Intarcia Therapeutics, Inc.	Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
IL267736B2 (en)	2017-01-03	2024-03-01	Intarcia Therapeutics Inc	Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
KR102665710B1 (en)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	GLP-1 composition and its uses
KR102647171B1 (en)	2018-02-02	2024-03-15	노보 노르디스크 에이/에스	Solid composition comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
AU2019329686A1 (en)	2018-08-27	2020-12-03	Regeneron Pharmaceuticals, Inc.	Use of raman spectroscopy in downstream purification
CN120647747A (en)	2018-10-11	2025-09-16	因塔西亚治疗公司	Human amylin analog polypeptides and methods of use
JP7761567B2 (en)	2020-02-18	2025-10-28	ノヴォノルディスクアー／エス	Pharmaceutical preparations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4347374A (en)	1980-07-21	1982-08-31	Merck & Co., Inc.	Acid addition salts of N-trityl-α-fluoromethylhistidine enantiomer derivatives
US5118666A (en)	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
ATE110083T1 (en) *	1986-05-05	1994-09-15	Gen Hospital Corp	INSULINOTROPIC HORMONE.
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
JP3262329B2 (en)	1990-01-24	2002-03-04	アイ．バックレイ，ダグラス	GLP-1 analog useful for the treatment of diabetes
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
WO1992018531A1 (en)	1991-04-09	1992-10-29	F. Hoffmann-La Roche Ag	Growth hormone releasing factor analogs
DK36392D0 (en)	1992-03-19	1992-03-19	Novo Nordisk As	USE OF CHEMICAL COMPOUND
RU2128663C1 (en)	1992-06-15	1999-04-10	Скиос Инк.	Derivatives of polypeptide showing insulinotropic activity, pharmaceutical composition, methods of enhancement of insulin effect, methods of treatment of diabetic patients
NZ250844A (en)	1993-04-07	1996-03-26	Pfizer	Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
WO1995005848A1 (en)	1993-08-24	1995-03-02	Novo Nordisk A/S	Protracted glp-1
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
KR20010071666A (en) *	1998-06-30	2001-07-31	한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느	Seeding crystals for the preparation of peptides or proteins
AU2001228327A1 (en) *	2000-01-31	2001-08-14	Novo-Nordisk A/S	Crystallisation of a glp-1 analogue
CA2417100A1 (en) *	2000-08-02	2002-02-07	Theratechnologies Inc.	Modified peptides with increased potency
ATE437891T1 (en) *	2000-12-07	2009-08-15	Lilly Co Eli	GLP-1 FUSION PROTEINS

2001
- 2001-11-30 AU AU2002228608A patent/AU2002228608A1/en not_active Abandoned
- 2001-11-30 EP EP01989720A patent/EP1351984A2/en not_active Withdrawn
- 2001-11-30 WO PCT/US2001/043167 patent/WO2002048192A2/en not_active Ceased
- 2001-11-30 US US10/450,042 patent/US7199217B2/en not_active Expired - Fee Related
- 2001-12-06 WO PCT/US2001/043183 patent/WO2002048183A2/en not_active Ceased
- 2001-12-06 WO PCT/US2001/043188 patent/WO2002047715A2/en not_active Ceased
- 2001-12-06 AU AU2002239262A patent/AU2002239262A1/en not_active Abandoned
- 2001-12-06 AU AU2002233929A patent/AU2002233929A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1351984A2 (en)	2003-10-15
WO2002048192A2 (en)	2002-06-20
WO2002048192A3 (en)	2003-08-07
AU2002239262A1 (en)	2002-06-24
WO2002047715A2 (en)	2002-06-20
US20040132647A1 (en)	2004-07-08
US7199217B2 (en)	2007-04-03
WO2002047715A3 (en)	2003-01-30
WO2002048183A3 (en)	2003-06-05
WO2002048183A2 (en)	2002-06-20
AU2002233929A1 (en)	2002-06-24

Publication	Publication Date	Title
AU2002228608A1 (en)	2002-06-24	Amidated glucagon-like peptide-1
AU2002322403A1 (en)	2003-03-10	Glucagon-like peptide-1 analogs
IL153453A0 (en)	2003-07-06	Glucagon-like peptide-1 analogs
AU2003239478A1 (en)	2003-12-22	Modified glucagon-like peptide-1 analogs
AU6586298A (en)	1998-10-22	Glucagon-like peptide-1 analogs
AU4497201A (en)	2001-10-15	Conducting material
AU2001284418A1 (en)	2002-06-06	Novel polypeptide
AU8441801A (en)	2002-03-13	Novel polypeptide
GB0015761D0 (en)	2000-08-16	Polypeptide
AU2001288220A1 (en)	2002-03-22	Hyperglycosylated polypeptides
GB0127017D0 (en)	2002-01-02	New polypeptide
AU2001266336A1 (en)	2002-01-21	Body-buried electrode
AU2002211324A1 (en)	2002-04-08	Oxidoreductases
GB0025572D0 (en)	2000-12-06	New polypeptide
GB0120704D0 (en)	2001-10-17	Polypeptide
AU2002224056A1 (en)	2002-06-03	Novel polypeptide
GB0027537D0 (en)	2000-12-27	New polypeptide
AU2001248535A1 (en)	2002-03-13	Limit switch
AU2002231050A1 (en)	2002-07-01	Oxidoreductases
GB0012199D0 (en)	2000-07-12	New polypeptide
GB0013239D0 (en)	2000-07-19	Polypeptide
AU2001234855A1 (en)	2001-08-14	Neuropeptide-like polypeptide zpep17
AU2002225532A1 (en)	2002-07-08	Silver-dispersing polypeptides
AUPR112700A0 (en)	2000-11-23	Peptide nitroanilides
GB0019859D0 (en)	2000-09-27	New polypeptide